-one
Chemicals with a ketone group.
- Drugs ending in -one: 115
- Approved somewhere: 38
- With a US drug page: 33
- Stem
- -one
- Class
- Chemicals with a ketone group
Approved and clinical-stage drugs in ChEMBL whose names ending in -one, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Atovaquone | Approved | MT-CYB | Cytochrome b inhibitor |
| Chlorthalidone | Approved | SLC12A3 | Thiazide-sensitive sodium-chloride cotransporter inhibitor |
| Dapsone | Approved | FOLP1 | Dihydropteroate synthase 1 inhibitor |
| Deferiprone | Approved | — | Unknown |
| Diflorasone diacetate | Approved | NR3C1 | Glucocorticoid receptor agonist |
| Edaravone | Approved | — | Unknown |
| Fluticasone furoate | Approved | NR3C1 | Glucocorticoid receptor agonist |
| Fluticasone propionate | Approved | NR3C1 | Glucocorticoid receptor agonist |
| Ixabepilone | Approved | Tubulin | Tubulin inhibitor |
| Lurasidone | Approved | HTR2A, DRD2 | Serotonin 2a (5-HT2a) receptor antagonist |
| Medrysone | Approved | NR3C1 | Glucocorticoid receptor agonist |
| Menadione | Approved | — | — |
| Methadone | Approved | OPRM1 | Mu opioid receptor agonist |
| Methylnaltrexone | Approved | OPRM1 | Mu opioid receptor antagonist |
| Molindone | Approved | DRD2, HTR2A | Dopamine D2 receptor antagonist |
| Nefazodone | Approved | SLC6A4, HTR2A, HTR2C, SLC6A2 | Serotonin transporter inhibitor |
| Paramethadione | Approved | Voltage-gated T-type calcium channel | Voltage-gated T-type calcium channel blocker |
| Phenindione | Approved | VKORC1 | Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor |
| Phytonadione | Approved | — | — |
| Pirfenidone | Approved | — | Unknown |
| Primidone | Approved | GABA-A receptor; anion channel, Sodium channel alpha subunit | GABA-A receptor; anion channel positive allosteric modulator |
| Spironolactone | Approved | NR3C2 | Mineralocorticoid receptor antagonist |
| Sulfoxone | Approved | FOLP1 | Dihydropteroate synthase 1 inhibitor |
| Trazodone | Approved | SLC6A4, HTR2A, HTR2C | Serotonin transporter inhibitor |
| Trimethadione | Approved | Voltage-gated T-type calcium channel | Voltage-gated T-type calcium channel blocker |
| Vilazodone | Approved | SLC6A4, HTR1A | Serotonin transporter inhibitor |
| Dordaviprone | Phase 3 | — | Unknown |
| Metyrapone | Phase 3 | CYP11B1 | Cytochrome P450 11B1, mitochondrial inhibitor |
| Testolactone | Phase 2 | CYP19A1 | Cytochrome P450 19A1 inhibitor |
| Anisindione | — | GGCX | Vitamin K-dependent gamma-carboxylase inhibitor |
| Chlormezanone | — | — | Unknown |
| Furazolidone | — | DNA | DNA inhibitor |
| Metaxalone | — | — | Unknown |
| Acetarsone | Approved | — | Unknown |
| Benzhydrocodone | Approved | Opioid receptors; mu/kappa/delta | Opioid receptors; mu/kappa/delta agonist |
| Dimethicone | Approved | — | Unknown |
| Enoximone | Approved | PDE3A, PDE3B | Phosphodiesterase 3 inhibitor |
| Fluindione | Approved | — | — |
| Hydrocodone | Approved | Opioid receptors; mu/kappa/delta | Opioid receptors; mu/kappa/delta agonist |
| Hydroquinone | Approved | — | — |
| Idebenone | Approved | — | Antioxidant and mitochondrial electron carrier |
| Norethindrone acetate | Approved | PGR | Progesterone receptor agonist |
| Oxycodone | Approved | OPRM1 | Mu opioid receptor agonist |
| Toloxatone | Approved | MAOA | Monoamine oxidase A inhibitor |
| Ziprasidone | Approved | HTR2A, HTR2C, DRD2 | Serotonin 2a (5-HT2a) receptor antagonist |
| Apabetalone | Phase 3 | Bromodomain and extra-terminal motif (BET) | Bromodomain and extra-terminal motif (BET) inhibitor |
| Apaziquone | Phase 3 | DNA | DNA inhibitor |
| Clobetasone butyrate | Phase 3 | — | Unknown |
| Eperisone | Phase 3 | — | — |
| Esmethadone | Phase 3 | — | — |
| Fluticasone | Phase 3 | — | — |
| Glutathione | Phase 3 | — | — |
| Hydronidone | Phase 3 | — | — |
| Isoflavone | Phase 3 | — | — |
| Nibrozetone | Phase 3 | — | — |
| Norethindrone | Phase 3 | PGR | Progesterone receptor agonist |
| Oxiglutatione | Phase 3 | GSR | Glutathione reductase other |
| Patupilone | Phase 3 | Tubulin | Tubulin stabiliser |
| Povidone | Phase 3 | — | — |
| Recoflavone | Phase 3 | — | — |
| Simethicone | Phase 3 | — | Antifoaming agent |
| Simeticone | Phase 3 | — | Anti-gas, surfactant |
| Thiazolidinedione | Phase 3 | — | — |
| Tolperisone | Phase 3 | — | — |
| Vatiquinone | Phase 3 | NQO1 | Quinone reductase 1 modulator |
| Adrenalone | Phase 2 | — | — |
| Bone morphogenetic protein 2 | Phase 2 | — | — |
| Carboquone | Phase 2 | — | — |
| Clorindione | Phase 2 | — | — |
| Difetarsone | Phase 2 | — | — |
| Diphenadione | Phase 2 | — | — |
| Epothilone d | Phase 2 | Tubulin | Tubulin stabiliser |
| Flavone | Phase 2 | — | — |
| Fluanisone | Phase 2 | — | — |
| Flumedroxone | Phase 2 | — | — |
| Halofuginone | Phase 2 | — | — |
| Hymecromone | Phase 2 | — | — |
| Ipriflavone | Phase 2 | — | — |
| Isobromindione | Phase 2 | — | — |
| Itruvone | Phase 2 | — | — |
| Ketobemidone | Phase 2 | — | — |
| Lapachone | Phase 2 | — | — |
| Levomethadone | Phase 2 | — | — |
| Lucanthone | Phase 2 | — | — |
| Macozinone | Phase 2 | DPRE1 | FAD-dependent decaprenylphosphoryl-beta-D-ribofuranose 2-oxidase inhibitor |
| Menaquinone 6 | Phase 2 | — | — |
| Mephenoxalone | Phase 2 | — | — |
| Methylone | Phase 2 | — | — |
| Morclofone | Phase 2 | — | — |
| Napazimone | Phase 2 | — | — |
| Nepinalone | Phase 2 | — | — |
| Nizofenone | Phase 2 | — | — |
| Normethadone | Phase 2 | — | — |
| Oxetorone | Phase 2 | — | — |
| Phanquone | Phase 2 | — | — |
| Sagopilone | Phase 2 | Tubulin | Tubulin stabiliser |
| Tanshinone iia sulfonic acid | Phase 2 | — | — |
| Terizidone | Phase 2 | — | — |
| Thymoquinone | Phase 2 | — | — |
| Tilorone | Phase 2 | — | — |
| Tolimidone | Phase 2 | LYN | Tyrosine-protein kinase Lyn positive allosteric modulator |
| Trepibutone | Phase 2 | — | — |
| Triaziquone | Phase 2 | — | — |
| Daniquidone | Phase 1 | — | — |
| Diphencyprone | Phase 1 | — | — |
| Mephedrone | Phase 1 | — | — |
| Methylpyrrolidone | Phase 1 | — | — |
| Ochromycinone | Phase 1 | — | — |
| Chlormadinone acetate | — | PGR | Progesterone receptor modulator |
| Ethadione | — | — | — |
| Exifone | — | — | Unknown |
| Methaqualone | — | GABA-A receptor; anion channel | GABA-A receptor; anion channel positive allosteric modulator |
| Piperidione | — | — | — |
| Pyrithione | — | — | Unknown |
| Pyrovalerone | — | SLC6A2, SLC6A3 | Monoamine transporters; Norepinephrine & dopamine inhibitor |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO